What is HC Wainwright’s Forecast for Liquidia Q2 Earnings?

Liquidia Co. (NASDAQ:LQDA) – Research analysts at HC Wainwright issued their Q2 2025 EPS estimates for Liquidia in a note issued to investors on Thursday, March 20th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.46) per share for the quarter. HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million.

Other equities analysts also recently issued research reports about the stock. Scotiabank raised their target price on shares of Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a research note on Thursday. Needham & Company LLC increased their price target on shares of Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wells Fargo & Company started coverage on shares of Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $26.63.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $15.12 on Friday. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.99. The company has a 50 day simple moving average of $14.79 and a two-hundred day simple moving average of $12.18. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -9.28 and a beta of 0.07.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets increased its holdings in Liquidia by 735.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after acquiring an additional 123,402 shares during the last quarter. Barclays PLC increased its holdings in Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock valued at $999,000 after acquiring an additional 72,591 shares during the last quarter. Whitefort Capital Management LP increased its holdings in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after acquiring an additional 927,546 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock valued at $2,354,000 after acquiring an additional 210,753 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after acquiring an additional 230,820 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

Insider Transactions at Liquidia

In other news, insider Rajeev Saggar sold 6,249 shares of the firm’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the sale, the insider now directly owns 270,388 shares in the company, valued at $3,185,170.64. This trade represents a 2.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Russell Schundler sold 16,393 shares of the firm’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the sale, the general counsel now owns 573,478 shares in the company, valued at $6,755,570.84. The trade was a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock worth $843,326 in the last 90 days. 30.10% of the stock is currently owned by insiders.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).